COVID-19 cases are increasing considerably around the world. According to reports, CP therapy affects the mortality of the plasma donor. Indian Council of Medical Research (ICMR) did a countrywide study over the effectiveness of Convalescent Plasma (CP) therapy in treating Covid-19 patients and they found no link to the therapy is effective in reducing mortality or helping COVID positive patients recover quickly.
ICMR conducted the study in 30 Government and private hospitals covering 464 patients including 35 from Gandhi Hospital in Hyderabad between April 22 and July 14. The conclusion is being hailed as the world’s first Randomised Controlled Trial (RCT) on CP therapy in COVID patients, is also a cautionary tale for private health care institutions, voluntary organisations and healthcare workers who have advocated the tool, creating unnecessary hype and demand for plasma and blood donation during the ongoing pandemic.
The ICMR officials said that "The use of CP therapy as a treatment for Covid-19 has received support for off-label use in India. This authorisation has been correlated by questionable practices such as calls for donors on social media, and the sale of CP in the black market with expensive price tags in India. The application of CP therapy did not mean that it will surely reduce the symptoms of the virus. The total of 464 patients participated in the study, out of which 235 were administered CP therapy while 228 were provided Best Standard Care (BSC). Out of the 235 who received CP therapy, 34, (13.6 per cent) died. Out of the 228 positive patients who were given BSC, 31 participants (14.6 per cent) died. The ICMR clearly said that there were no differences in outcomes between the study participants receiving CP with compared to patients who were on BSC.
Also Read:
This veteran Bollywood actress expressed displeasure over Kangana's statements
Realme 7 to available for sale at 12 pm today, Grab amazing offers
Realme Electric Toothbrush sale starts today, check out details here
